An interventional study of Teen MMS and Parent Facebook in Skin Cancer Prevention, sponsored by Rutgers, The State University of New Jersey. Recruiting at 1 site in United States. Open to participants aged 13 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 381 studies in Skin Neoplasms with a site in United States — 64 open to participants now, 98 under way, 7 of them phase 3. Skin Neoplasms · United States.
Among the 381 studies in Skin Neoplasms with a site in United States, this one is the 89th largest by planned enrollment of the 290 interventional ones that give a count, is one of 17 that started in 2026, is one of 97 with no phase, reaches primary completion later than 58 of the 96 other live ones, and was the 372nd registered.
606 studies on the registry are indexed under Skin Neoplasms; 127 are open to participants now.
Browse Skin Neoplasms studies →64 of the 381 studies in Skin Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 18–29 · Healthy volunteers
Marissa Lobl · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Karam Khaddour, MD, MS · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 105 Skin Neoplasms studies recruiting now, 85 (81%) set no upper age limit and 9 (9%) stop at 75 or younger; 15 take children under 18; 25 take healthy volunteers.
This study: 13 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
381 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 84 · Phase 2 115 · Phase 3 26 · Phase 4 11
First in 1977; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is above the median of 55 across 410 interventional studies indexed under Skin Neoplasms.
Median enrollment 44 across the 290 interventional studies, 149 across the 80 observational. Of the 258 that completed or were terminated, 92 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
108 of 381 have an industry lead sponsor. The 10 most frequent:
Rutgers, The State University of New Jersey is the lead sponsor of 507 studies on the registry; 132 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 31 (79%) have results posted.
Rutgers, The State University of New Jersey has 4 studies filed under Skin Neoplasms — fewer than ten, so there is no comparison to draw.
34 of the studies in Skin Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT06947928Phase 3TuHURA Biosciences, Inc.Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | 2027-03-31 |
| NCT05634252Phase 3University of UtahUndergraduate Skin Cancer Prevention Trial | 2027-09-04 |
| NCT07931664The Center for Clinical and Cosmetic ResearchEvaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk. | 2026-11 |
| NCT07201376Dartmouth-Hitchcock Medical CenterAssessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically | 2026-11 |
Add all 34 to your calendar (.ics) → With an account.
Among the 381 studies in Skin Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this pilot clinical trial is to learn if a digital intervention to improve sun safety, Sun Safe Together (SST), is feasible and acceptable to teenagers and their parents.
Melanoma is a leading cause of invasive cancer in teens and young adults aged 15-39. Most skin cancers are preventable with skin protection such as minimizing UVR exposure and wearing protective clothing and sunscreen. However, teens have low levels of sun protection. Thus, interventions targeting skin cancer risk reduction among teens are needed. The proposed Sun Safe Together (SST) intervention is a 12-week program consisting of sun safety and general health messages sent via multimedia messaging service (MMS) to teens and via a private Facebook group for parents.
This pilot trial is a single arm test of SST to determine:
Inclusion Criteria:
Parents and teens are participating as dyads, meaning both the parent and the teen need to be deemed eligible based on the criteria below to be able to participate.
Teens
Parents/Guardians
Behavioral: Teen MMS · Behavioral: Parent Facebook
Teens will receive MMS messages regarding sun safety behaviors and other general health issues for 12 weeks.
Parents of teenagers join a private Facebook group where membership, activities, and content are only viewable by invited members. Content related to teen sun safety and general health will be posted for 12 weeks. Research staff will moderate the group.
Feasibility of recruitment
Feasibility of recruitment will be assessed by the proportion of eligible parent-teen dyads that enroll in the study
Time frame: Baseline
Acceptability of MMS intervention
Items were adapted from the Acceptability of Intervention and Feasibility of Intervention Measures to obtain participant feedback about the acceptability, feasibility, ease of use, and impact of the intervention. Individual items are rated on a 5-point likert scale from (1) Completely Disagree to (5) Completely Agree. Higher scores indicated greater acceptability.
Time frame: Immediately after the intervention
Engagement with MMS intervention
Proportion of messages viewed will be calculated to describe engagement.
Time frame: 3-months
Feasibility of Outcome Data Collection - 7-Day Diaries
Proportion of teens who complete 7-day diaries will be calculated.
Time frame: Baseline, 3-months, 6-months
Feasibility of Outcome Data Collection - UVR Dosimeter
Proportion of teens who return UVR dosimeter with usable data will be calculated.
Time frame: Baseline, 6 months
Retention
Proportion of enrolled teens who complete surveys at 3- and 6-months will be calculated.
Time frame: 3-months, 6-months
Plan to share: Yes — De-identified study data and associated documentation will be made available to the research community through the Data Sharing for Demographic Research (DSDR) data repository hosted at the Inter-university Consortium for Political and Social Research (ICPSR).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be made available by the time of associated publication or the end of grant funding (whichever is later). The duration of preservation and sharing of the data will be indefinite.
Access criteria: De-identified human subject data will be made available in the Inter-university Consortium for Political and Social Research (ICPSR) data repository, which restricts access to the data to qualified investigators with an appropriate research question who complete a data use agreement and provide a data security plan.
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Dec 2027, 16 months later.
Of 94 non-industry interventional studies with no phase under Skin Neoplasms, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 49. This study's planned 16 months is below that.
Counting every sponsor, half of 116 studies reached it within 27 months; a quarter within 10 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rutgers, The State University of New Jersey →